Mechanisms of resistance to imatinib in chronic myeloid leukemia (CML) patients in chronic phase (CP) who achieved durable complete cytogenetic responses (CCR).

被引：0

作者：

Piazza, R

Magistroni, V

Tornaghi, L

Andreoni, F

Bungaro, S

Cazzaniga, G

Biondi, A

Pogliani, E

Varella-Garcia, M

Corneo, G

Gambacorti-Passerini, C

机构：

[1] Natl Canc Inst, I-20133 Milan, Italy

[2] Univ Milano Bicocca, Osped San Gerardo, Monza, Italy

[3] Univ Colorado, Ctr Canc, Denver, CO 80262 USA

来源：

BLOOD | 2003年 / 102卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4996

引用

页码：319B / 319B

页数：1

共 50 条

[21] Dasatinib Time to and Durability of Major and Complete Cytogenetic Response (MCyR and CCyR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Baccarani, Michele
Rosti, Gianantonio
Saglio, Giuseppe
Cortes, Jorge
Stone, Richard
Niederwieser, Dietger W.
Bleickardt, Eric
Sinha, Ritwik
Simonsson, Bengt
BLOOD, 2008, 112 (11) : 172 - 172
[22] Phase 2 study of dasatinib in Chinese patients with chronic myeloid leukemia (CML) in chronic phase (CP) or advanced phase who are resistant to or intolerant of imatinib (IM)
Wang, Jianxiang
Huang, Xiaojun
Hu, Jianda
Li, Jianyong
Jin, Jie
Meng, Fanyi
Shen, Zhixiang
Liu, Ting
Wu, Depei
Wang, Jianmin
LEUKEMIA & LYMPHOMA, 2013, 54 : 3 - +
[23] Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib
Marin, D
Kaeda, JS
Andreasson, C
Saunders, SM
Bua, M
Olavarria, E
Goldman, JM
Apperley, JF
CANCER, 2005, 103 (09) : 1850 - 1855
[24] Clinical significance of molecular monitoring in chronic myeloid leukemia (CML) in chronic phase (CP) with imatinib therapy
Cortes, J
Talpaz, M
O'Brien, S
Jones, D
Luthra, R
Garcia-Manero, G
Giles, F
Shan, J
Verstovsek, S
Rios, MB
Kantarjian, H
BLOOD, 2004, 104 (11) : 81A - 81A
[25] Cytogenetic responses in chronic myeloid leukemia patients treated with imatinib mesylate
Babameto-Laku, A.
Mokin, V.
Cikuli, M.
Xhumari, P.
CHROMOSOME RESEARCH, 2005, 13 : 158 - 158
[26] Better molecular response (MR) to imatinib (IM) in early chronic phase (CP) versus late CP chronic myeloid leukemia (CML) patients (pts) in complete cytogenetic response (CCR): A comparison at 24 months of 2 clinical trials of the GIMEMA working party on CML on behalf of the GIMEMA working party on chronic myeloid leukemia (GIMEMA-CML).
Poerio, A
Amabile, M
Iacobucci, I
Soverini, S
Colarossi, S
Ottaviani, E
Terragna, C
Grafone, T
Luatti, S
Castagnetti, F
Pane, F
Saglio, G
Russo, D
Rosti, G
Baccarani, M
Martinelli, G
BLOOD, 2005, 106 (11) : 319A - 319A
[27] HIGH DOSE IMATINIB TO ACHIEVE MOLECULAR RESPONSES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN LATE CHRONIC PHASE AND COMPLETE CYTOGENETIC RESPONSE: IS IT WORTHWHILE?
Stagno, F.
Vigneri, P.
Massimino, M.
Del Fabro, V.
Stella, S.
Berretta, S.
Messina, A.
Di Raimondo, F.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 433 - 433
[28] Cytogenetic and molecular responses in German patients with chronic-phase chronic myeloid leukemia (CP-CML) in a prospective observational study (SIMPLICITY)
Repp, R.
Hehlmann, R.
Linde, H.
Reiser, M.
Tesch, H.
Foreman, A.
Schreiner, L.
Hillig, G.
Oncology Research and Treatment, 2015, 38 : 132 - 132
[29] Homoharringtonine in combination with imatinib for patients with CML who have achieved partial or complete cytogenetic responses.
Le Dieu, R
Bua, M
Andreasson, C
Olavarria, E
Goldman, JM
Apperley, JF
Maria, D
BLOOD, 2004, 104 (11) : 289A - 289A
[30] The treatment cost to achieve a complete cytogenetic response in imatinib resistant chronic phase (CP) chronic myelogenous leukemia (CML) patients:: Nilotinib vs. dasatinib
Mataveli, Fabio D.
Feng, Weiwei
Calabro, Alessandra
Mendes, Wellington
Hungria, Vania
BLOOD, 2007, 110 (11) : 977A - 977A

← 1 2 3 4 5 →